Controlling the ‘social life’ of proteins aims to transform drug discovery
A new £3.4 million programme will develop new tools to understand which interactions between proteins in the human body are relevant to disease. Currently, only a handful of drugs in clinical use work by targeting protein-protein interactions. A new £3.4 million programme will develop new tools to understand which interactions between proteins in the human body are relevant to disease.